References
- Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119:108-21S
- Schelleman H, Bilker WB, Brensinger CM, et al. Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med 2010;123:151-7
- Simonson SG, Martin PD, Mitchell PD, et al. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 2005;45:927-34
- Inagaki Y, Hunt T, Arana B, et al. Drug–drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers. J Clin Pharmacol 2011; 51:1302-9
- Jindal D, Tandon M, Sharma S, et al. Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects. Eur J Clin Pharmacol 2005;61:621-5
- Redman AR. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy 2001;21:235-42
- Sakaeda T, Fujino H, Komoto C, et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res 2006;23:506-12
- Iliadis EA, Konwinski MF. Lovastatin during warfarin therapy resulting in bleeding. Pa Med 1995;98:31
- Hoffman HS. The interaction of lovastatin and warfarin. Conn Med 1992;56:107
- Trenque T, Choisy H, Germain ML. Pravastatin: interaction with oral anticoagulant? BMJ 1996;312:886
- Trilli LE, Kelley CL, Aspinall SL, et al. Potential interaction between warfarin and fluvastatin. Ann Pharmacother 1996;30:1399-402
- Kline SS, Harrell CC. Potential warfarin–fluvastatin interaction. Ann Pharmacother 1997;31:790
- Hickmott H, Wynne H, Kamali F. The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb Haemost 2003;89:949-50
- CDER/CBER Guidance for Industry on Drug Interaction Studies. Drug Interaction Studies – Study Design, Data Analysis, and Implications for Dosing and Labeling. FDA Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Guidance for Industry on Drug Interaction Studies. 2006. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf [Last accessed 27 October 2011]